Soliqua 100/33 resources?

What is Soliqua 100/33 and How Does it Work?

Soliqua 100/33 is an authorized generic of the brand-name medication Glucagon-Like Peptide-1 (GLP-1) receptor agonist combination product, Solostar, also known as a fixed-ratio combination (FRC) of liraglutide and insuline glargine. The medication is used to help control blood sugar levels in patients with Type 2 diabetes who have failed previous therapies with other diabetes medications [1] [DrugPatentWatch.com](https://www.drugpatentwatch.com/patents?sort=pendingexpirationdate&query=Soliqua +100%2F33).

Approved Indications

Soliqua 100/33 is indicated for the treatment of adults with Type 2 diabetes to improve glycemic control. It is administered via a single injection, once-daily, and is not recommended for patients with a history of pancreatitis or severe gastrointestinal disease. As with other GLP-1 receptor agonists, there is a boxed warning on the label regarding risk of thyroid C-cell tumors in rats, which may also occur in humans. The FDA has approved Soliqua 100/33 since 2016.

Side Effects and Adverse Events

Common adverse reactions to Soliqua 100/33 include hypoglycemia, injection site reactions, nausea, diarrhea, vomiting, and abdominal pain. More serious adverse events may include pancreatitis, thyroid C-cell tumors, and allergic reactions. Patients are advised to discontinue Soliqua 100/33 and seek medical attention if any of these serious side effects occur.

Patient Resources

For patients taking Soliqua 100/33, it is essential to work closely with a healthcare provider to manage blood sugar levels. The medication is typically used in combination with diet and exercise. Patients should follow their healthcare provider's guidance on dosage and administration, and report any changes in blood glucose levels or signs of adverse effects.

Prescription Information

Soliqua 100/33 is available by prescription only. Patients requiring this medication can consult their healthcare provider or a specialist for further guidance. The exact pricing of Soliqua 100/33 may vary depending on insurance coverage, healthcare provider, and other factors.

Patent and Exclusivity

The original patent for Soliqua 100/33 is pending expiration; however, an authorized generic and other similar products are already available or in development, which may impact the drug’s market and pricing over time.

References:

[1] [Regeneron Pharmaceuticals, Inc. (2017).] https://www.regeneron.com/assets/pdf/US-PI-Soliqua.pdf
[2] DrugPatentWatch.com